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Pre’cis 
Management of glaucoma in pregnancy is challenging. The optimal treatment option 
needs to provide adequate control of IOP for the mother while maintaining minimal risk 
for the fetus. 
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Abstract 
Management of glaucoma during pregnancy represents a challenge for the physician. 
Important disease and patient health decisions begin even prior to conception and 
continue throughout pregnancy and breastfeeding. Data on this topic is limited due to 
ethical and legal constraints and challenges of conducting large, prospective, and 
randomized clinical trials on this patient population. Our review suggests that 
individually, intraocular pressure is lower in a pregnant woman when compared to a non-
pregnant woman. Importantly, the medical management of glaucoma during pregnancy 
poses special challenges due to the possibility of adverse effects of medications on the 
fetus and newborn. Laser trabeculoplasty and traditional filtration surgery, as well as 
minimally invasive glaucoma surgery, represent non-drug management options.  Thus, 
managing glaucoma in pregnancy is a delicate balance between treatment to prevent 
damage to the optic nerve in the mother and avoidance of interventions potentially 
harmful to the fetus. This literature review of published individual and population-based 
studies was performed in order to explore current knowledge and guidelines in the 
management of glaucoma in pregnancy. 
Keywords: glaucoma, pregnancy, lactation, intraocular pressure, anti-glaucoma 
medications  
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Epidemiology  
Managing chronic diseases in pregnant women poses a unique challenge for physicians; 
the risks of limiting treatment options for the mother and the risk of exposing the fetus to 
disease management interventions. In addition, there is the added risk due to alterations 
in the physiology and hemodynamic state of the pregnant woman. Dueling paradigms of 
treatment and safety need to be carefully evaluated and glaucoma is no exception to this 
challenge.
1
 Importantly ophthalmologists often have limited confidence in addressing this 
subject. Vaideanu et al. conducted a survey of all consultant ophthalmologists in the 
United Kingdom, and their results indicated that many ophthalmologists are uncertain 
about the optimal strategy in the management of glaucoma in pregnancy.
2
 Due to the 
ethical and legal constraints of conducting large, prospective, and randomized clinical 
trials on this patient population, the data on this subject is limited.
3
 Without rigorous 
clinical research, physicians must rely on alternative forms of research and scientific 
literature to guide them in their decision making processes. There are case reports
 
which 
describe women with glaucoma whose intraocular pressure (IOP) was difficult to control 
during pregnancy, despite medical and surgical intervention. Therefore it is important for 
physicians to be careful and knowledgeable while treating this patient population.
4,5
 
Glaucoma has traditionally been considered a disease of old age, a survey of 3,494 
patients under 40 who were examined in an urban optometric center showed that 0.4% of 
the sample had glaucoma and an additional 0.2% had suspected glaucoma.
6
 Thus 
although the prevalence is not very high in women of childbearing age, the decision to 
have children can significantly impact glaucoma management strategies.  
This review explores the medical management of glaucoma in pregnancy and examines 
the various antiglaucoma drugs and their safety and efficacy during pregnancy and 
lactation. Articles from Pubmed published from1952-2017 were identified by using the 
keywords, glaucoma, pregnancy, lactation, intraocular pressure, and antiglaucoma 
medications. 
Preconception planning  
Women of childbearing age may have a history of glaucoma and already be on a 
treatment regimen. The situation is more complicated if pregnancy is unplanned since the 
greatest risk of treatment induced adverse effects to the fetus is in the first trimester of 
pregnancy: during organogenesis.
7
 Preconception counseling is the best recommended 
strategy in women of childbearing age with glaucoma. This helps women to understand 
potential benefits and risks of various treatment modalities, promotes better cooperation 
in evaluating IOP levels and fluctuations at more frequent intervals, as well as evaluating 
optic nerve and visual field function in order to assess the baseline status. It also helps to 
determine the risk of observation when treatment is discontinued, or fewer medications 
are entertained during pregnancy. If the glaucoma is uncontrolled, laser treatment or 
surgical intervention may be undertaken prior to conception to avoid side-effects of 
glaucoma medications during pregnancy. 
The eye in pregnancy 
Multiple studies have demonstrated that IOP in pregnant females is on average lower 
than non-pregnant females.
8
 Initial theories focused on the hormonal levels that fluctuate 
during pregnancy, such as estrogen, relaxin, progesterone, and β-human chorionic 
gonadotrophin.
9-10
 Later it was shown that the aqueous humor formation rate does not 
change during pregnancy, but that outflow facility increases during pregnancy, causing a 
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decrease in IOP.
10
 Ebeigbe et al, have shown that with advancing pregnancy, IOP 
decreases from 14.7mmHg in the first trimester to 11.0mmHg in the third trimester.
11
 In 
addition, lower IOP has been associated with less severe fluctuations in IOP over the 
course of the day during the third trimester.
12
 The ocular hypotensive effects of 
pregnancy also extend to patients with preexisting ocular hypertension, although the time 
course differed between patient groups. Qureshi et al. found that, in normotensives, the 
significant decrease in IOP occurred in the 18
th
 week, while the decrease occurred later in 
the course of pregnancy in ocular hypertensive patients. In ocular hypertensive subjects, 
pregnancy may even bring the IOP down to within normal limits.
13
  
Systemic hypertension has been shown to influence IOP in non-pregnant patients; 
however, the evidence in the pregnant population is mixed. Some studies found no 
significant difference in IOP in the third trimester between hypertensive and 
normotensive pregnant women
14
, while others found that the IOP in pregnant 
hypertensives was higher than the non-hypertensive pregnant women in the third 
trimester.
15
  It was also found that the decrease in IOP was independent of systemic BP, 
body weight and height.
9
 Evidence has also shown that multigravida have lower IOP than 
primigravidae, who in turn have lower IOP than non-pregnant women, although the exact 
mechanism of this difference is largely unknown.
16
 Despite our understanding of IOP 
changes that occur in non-glaucomatous pregnant females, we have limited data in 
pregnant patients with glaucoma. Brauner et al. followed 15 pregnant women with 
glaucoma throughout pregnancy and their individual disease course was mixed. In over 
half (57.1%) of the eyes, IOP remained stable and there was no progression in the visual 
field. In 17.9% of eyes, there was visual field progression with stable or increased IOP. In 
17.9% of eyes remained stable despite increasing IOP and the remaining eyes (7.1%) 
were non-compliant to medications.
17
 While the natural course of IOP in healthy people 
decreases throughout pregnancy, the course of glaucoma during pregnancy is variable, 
and women must be monitored closely during pregnancy. Thus, managing IOP in 
pregnant women remains a challenge which is necessary to prevent pregnancy related 
vision loss. 
Some studies claimed that hormonal changes during pregnancy do not affect corneal 
biomechanics,
18
 while several other studies found that pregnancy was associated with 
increase corneal curvature, corneal volume, corneal innervation, and corneal thickness.
 19-
22
 This may be because of the various hormones on the cornea during pregnancy. 
Pregnancy is known to worsen diabetic retinopathy, as well as retinal detachments, 
central serous chorioretinopathy, and retinal vascular occlusive diseases. Retinal blood 
vessels have classically been examined as a way to monitor pre-eclampsia and 
eclampsia.
23-26
 The choroid is a highly vascularized tissue characterized by the highest 
blood flow to tissue volume ratio in the whole body. This makes it especially susceptible 
to hemodynamic and hormonal changes taking place in pregnancy, which may affect its 
thickness.
27
 Choroidal thickness has been found to be increased in pregnant versus non-
pregnant women,
28-31
 and this thickening was maximum in the second trimester of 
pregnancy.
32 
The circulating blood volume increases from week 5-6 of pregnancy, and 
most rapidly from weeks 20 to 24. As a result of the effect on the hemodynamics of the 
cardiovascular system in pregnancy, a decrease in vascular resistance prevails over the 
effect of an increase in blood volume; and thus results in a decrease in systolic and 
diastolic pressure.
33
 Laser Speckle Flowgraphy (LSFG) parameters have shown a 
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decrease in resistance in the retinal blood vessels in normal pregnancy. Flow acceleration 
index (FAI) and resistive index (RI) values showed a significant decrease in the 3rd 
trimester, while blowout score (BOS) increased in the 3
rd
 trimester and mean blur rate 
(MBR) showed no significant changes throughout pregnancy. In addition, mean arterial 
pressure (MAP) was negatively correlated with FAI and RI while positively correlated 
with BOS. Thus, retinal vasculature provides a highly sensitive reflection of 
physiological changes in vascular resistance due to pregnancy.
34, 35
  
Labor in Glaucomatous Patients 
Some studies have postulated that IOP during labor can vary depending on the stage of 
labor.
36
 Sixty-four (64) non-glaucomatous patients were evaluated during each stage of 
labor. This study found that mean IOP increased by 1.4 mm Hg during the course of labor 
which was found to be statistically significant, and then decreased by 3.0 mm Hg 
immediately after delivery. The IOP returned to pre-labor levels in all patients by 72 
hours after delivery. It was postulated that an increase in oxytocin levels during labor 
leads to capillary constriction and a decrease in aqueous outflow.
36 
 More recent studies 
performed on patients who received epidural anesthesia showed a mild increase in IOP 
and mean ocular perfusion pressure during the second stage, but this was not statistically 
significant.
37
 There is no evidence in the literature linking oxytocin with a rise in IOP.
37
  
Whether this has any effect on the progression of glaucoma has not been studied, as the 
effects of a small change in IOP for a short period of time, on glaucomatous progression 
is unknown..
38
 While not a part of the natural disease process, loss of large amounts of 
blood  during labor may potentially lead to transient hypotension and ischemia, with an 
increased risk for optic nerve damage.
39
  
Medical Management of Glaucoma 
The pregnant (or planning to be pregnant) glaucoma patient presents a unique clinical 
challenge for ophthalmologists. The clinician is faced with balancing the risk of 
glaucomatous disease progression in the mother against the potential risks of 
interventions to the fetus or newborn child. The course of glaucoma in pregnancy may be 
complex. While numerous studies have supported the ocular hypotensive effects of 
pregnancy, including Qureshi et al. who found that patients with ocular hypertension also 
have reduced IOP in pregnancy,
15
 the IOP data in pregnant glaucoma patients remains 
undefined. In light of the limited and mixed results, it is important to evaluate each 
patient based on their individual glaucoma risk, need for treatment, and regular 
monitoring throughout pregnancy. Medical treatment of glaucoma carries a potential 
health risk to the developing fetus. Because of this potential risk, it is important to reduce 
the systemic absorption of topical glaucoma medications. Systemic absorption may be 
reduced by nasolacrimal occlusion (NLO), punctual plugging, or eyelid closure. 
Zimmerman et al. found that NLO or eyelid closure for 5 minutes reduced systemic 
absorption over 60%. Both NLO and eyelid closure are safe, simple and effective ways to 
minimize dosage as well as side effects.
40
  
When evaluating the individual risk of medications, it is useful to review the FDA 
Pregnancy Categories of various glaucoma medications (Table 1). While we do not have 
randomized clinical trials in pregnant glaucoma patients, animal studies and case reports 
can aid ophthalmologists when making treatment decisions and choosing pharmacologic 
therapies. The FDA Pregnancy Categories for medications include classes A, B, C, D and 
X,
41
 with glaucoma medications occupying classes B and C.
3
 To qualify as a Category A 
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medicine there must be human studies that have failed to demonstrate risk to the fetus. 
There are currently no randomized prospective human studies for glaucoma medications 
in pregnancy. Furthermore, they are unlikely to be performed in the future due to ethical 
conflicts. Category B medicines include those where animal studies fail to demonstrate a 
risk to the fetus, but there are not adequate studies in pregnant women to elevate to 
Category A. The Category C medications demonstrate adverse effects in animal fetuses, 
but again no adequate studies have been performed in humans. Category C medications 
may still benefit pregnant women despite the negative effects seen in animal models. 
Category D medications carry known human risk based on a history of adverse reactions, 
although their use may be warranted in some cases. Finally, Category X medications 
have shown fetal abnormalities in either humans or animals. The risks clearly outweigh 
the potential benefits from use of category X medications.
41
  
The most common preservative in anti-glaucoma drugs is benzalkonium chloride (BAK). 
Animal studies on rats have shown a dose-related increase in fetal resorption and death, 
as well as a reduction in litter size and weight. Minor defects in the sternum were seen in 
fetuses exposed to a single dose of 100 and 200 mg/ kg.
43
 The concentration of BAK in 
anti-glaucoma eye drops varies from 0.005% to 0.2%,
44
  In this dose, it can disrupt the 
lipid layer of the tear film and also cause evaporation of tears. It has also been shown to 
have cellular toxicity on caliciform cells. Systemically it may even cause a delayed type 
of hypersensitivity reaction (Type-IV).
44
 
Beta-blockers: Beta-blockers are one of the first line treatment options for glaucoma 
patients and are FDA pregnancy category C.
3
 This class of medication is typically 
prescribed as a topical preparation, but the IOP lowering effects occur with the systemic 
preparations as well. The topical beta blockers that are commonly used include timolol 
maleate, timolol hemihydrate, betaxolol, carteolol, levobunolol, and metipranolol. All of 
these medications, except for betaxolol, are non-selective beta antagonists. The non-
selective agents have both beta-1 and beta-2 antagonistic activity.
45, 46
 Beta-1 receptors 
are primarily located in cardiac tissue, and the effect of beta-1 selective antagonists is a 
decrease in heart rate.  Beta-2 receptors are primarily located on the arteries of skeletal 
muscle and bronchioles of the lungs, and beta-2 selective antagonists activation lead to 
bronchoconstriction. Betaxolol is a beta-1 selective antagonist; therefore, it avoids some 
of the systemic effects of the non-selective agents, although for IOP reduction it is less 
efficacious than non-selective medications. Additionally, carteolol, a non-selective beta 
antagonist, has intrinsic sympathetic activity and therefore some of the antagonistic 
actions are reduced.
47  
The beta blockers decrease IOP by decreasing aqueous humor production via inhibition 
of cAMP in the ciliary epithelium. The IOP lowering effects have been found with both 
systemic and topical beta-blocker use. While some ophthalmologists may be hesitant to 
use this medication in pregnant women, obstetricians frequently use systemic beta 
blockers in pregnancy to control hypertension. Some of the hesitation stems from both 
theoretical and reported concerns for neurological, cardiopulmonary, and growth 
restriction complications in the newborn.
48-50 
The neurological concerns stem from the 
side effects of lethargy, confusion, and depression seen from beta-blocker use. Studies 
support that by switching from timolol to betaxolol, which is a selective antagonist, the 
CNS effects are reduced.
 51,52
 
Data on the use of antiglaucoma medications, in particular beta-blockers, has yielded 
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conflicting conclusions. Ho et al. conducted a population-based study (n=244) in order to 
examine the relationship between the incidence of having a low-birth-weight (LBW) 
infant and the use of antiglaucoma medications during pregnancy. They concluded that 
while there was no significant difference in the risk of having LBW infants between 
mothers prescribed beta-blockers and mothers in the comparison cohort, there was a 
significantly higher risk of having a LBW infant for mothers prescribed other topical 
antiglaucoma medications compared to the control group.
53
 Similarly, Brauner et al found 
no significant complications including LBW.
17 
 Of particular note is that they instructed 
all pregnant women to use punctual occlusion after installation of eyedrops to decrease 
systemic absorption. On the other hand, Razeghinejad et al in a small study found a 
statistically significant reduction in birth weight in infants born to mothers on topical 
beta-blockers.
54
 However, it should be noted that their patients were on topical 
combination therapy.  Beta-blockers are known to affect cardiac physiology with side 
effects of bradycardia and possible arrhythmia. A published case report by Wagenvoort et 
al described a fetus with bradycardia and arrhythmia when the mother was on topical 
timolol. These side effects improved following a reduction in the medication 
concentration
55
 and other studies have shown no evidence of changes in heart rate.
56 
Furthermore, beta-blockers can be actively secreted into breast milk and cause potential 
adverse effects in breastfed infants. In one case study, the concentration of timolol in 
breast milk was determined to be six times that of the plasma following topical 
ophthalmic use
57
 and another study found betaxolol to be three times more concentrated 
in breast milk than in the plasma.
58
  
Sympathomimetics: These are the only topical antiglaucoma medications classified as 
category B
3
.  Non-selective agonists and selective alpha agonists like clonidine and 
apraclonidine are not used frequently in the treatment of chronic glaucoma due to the side 
effects such as nausea, vomiting, palpitations, and difficulty in micturition which are 
associated with chronic use.
59- 61
 Brimonidine is the only drug in this category which is 
used on a long-term basis. Animal studies on pregnant rats and rabbits have revealed no 
damage to the fetus at doses much higher than the dose used at therapeutic levels in 
humans.
62
 Although considered safe to use in pregnancy, brimonidine is thought to be 
secreted in breast milk and should be discontinued in the third trimester as it causes 
central nervous system depression, hypotension, and apnea in infants.
63,64
  
Carbonic anhydrase inhibitors: Acetazolamide and methazolamide are oral carbonic 
anhydrase inhibitors (CAI) used for glaucoma management. These agents are category C 
for use during pregnancy.
3
 Acetazolamide at high doses has been shown to produce birth 
defects in animals.
65,66
 However clinical or experimental studies looking at the adverse 
effects of acetazolamide on pregnancy outcomes in humans have shown mixed results.
52, 
67-69
 One isolated incidence of limb anomalies has been found in literature, but other 
studies
70,71
 have not shown any limb anomalies following systemic use of Carbonic 
anhydrase inhibitors in pregnancy. So if the clinical situation warrants the use of systemic 
acetazolamide, then the drug could be administered with appropriate informed consent. 
Animal studies have shown decreased weight gain in the offspring of lactating rats who 
have been exposed to very high doses of topical CAI.
72,73
 However, recent reports have 
shown mixed results in humans. It was earlier thought to be safe to use in humans
17
 but 
recently, there are a few reports of low birth weight
53
 and defects in renal tubular function 
in the newborn following maternal use of topical CAI.
74
 Although low plasma levels of 
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acetazolamide have been reported in infants exposed to the medication through breast 
milk,
75
 the American Academy of Pediatricians has approved the use of CAIs during 
lactation, provided there is close monitoring of oral formulations.
3
 
Prostaglandin analogs: Bimatoprost, latanoprost, travoprost, and tafluprost are 
prostaglandin-F2 analogs used as topical eye drops in patients with glaucoma. They 
belong to category C for use during pregnancy.
3
 Prostaglandins are also used 
systemically to induce labor by stimulating smooth muscle contraction. The contractile 
function has been demonstrated specifically of latanoprost, travoprost, and bimatoprost in 
non-pregnant uterus which had been isolated in rat models.
76
 Fortunately, there are no 
reports of premature labor in humans associated with the use of these drugs topically for 
glaucoma. There is no data available on the effect of tafluprost eye drops on the uterus. It 
has been shown that prostaglandin analogs are excreted in the breast milk of animals, 
although it is not known if they are excreted in the breast milk of humans. Whether or not 
topically administered medications reach plasma concentrations that could induce 
adverse effect on the pregnancy or on the fetus remains controversial.
77
 Although birth 
defects have been reported following the prenatal use of systemic prostaglandins,
78
 a 
small study by De Santis et al on 11 pregnant women showed that topical latanoprost 
exposure caused no adverse effects on either the pregnancy or the newborn.
79
  The 
difference in adverse events in this study compared to animal studies may be due to 
dosage levels.  While De Santis's study found no evidence for adverse outcomes, the 
study was small and involved a 46-year-old female with miscarriage; however, this may 
be due to her advanced age. Being prodrugs, latanoprost and travoprost have the 
advantage of being converted into the active form once they pass the cornea with 
increased intraocular penetration and decreased local and systemic side effects,
61
, 
however, use in the case of severe glaucoma uncontrolled with other topical medication 
has not been prospectively studied. Latanoprostene is another prostaglandin-F2 analog 
which has entered the market.
80 
A new class of drug which has entered the market is Netarsudil which is an inhibitor of 
Rho kinase and norepinephrine transporter.
81
 It increases outflow of aqueous humor and 
decreases episcleral venous pressure. However, there are no studies which have looked 
into its safety during pregnancy and lactation. 
Parasympathomimetics, Parasympathomimetics or cholinergic agents, are classified as 
category C drugs. Although pilocarpine and carbachol injected into the yolk sac have 
demonstrated teratogenic and adverse fetal effects in animals
82
 Kooner et al. found no 
association between congenital abnormalities and the use of topical cholinergic agents 
during the first 4 months of gestation.
60
  Cholinergic receptors are found on the placenta, 
and it is thought that they are linked to myometrial and placental prostaglandin release 
and regulation of placental perfusion.
83 
There are reports of hyperthermia, seizures, or 
restlessness in neonates and therefore these medications are generally avoided in the 
postpartum period.
84
 Due to the availability of safer and more effective drugs with other 
classes of antiglaucoma medications, parasympathomimetics are not used in management 
of glaucoma in pregnancy. (Table 2)  
Laser filtration procedure in Glaucoma 
When medical treatment fails or is not an option to control IOP or there is progression of 
visual field damage in a pregnant female with glaucoma, laser filtration options need to 
be considered.
85
 Laser procedures are useful to reduce or eliminate the use of medications 
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which may be potentially harmful to the fetus. When considering laser procedures, 
special consideration must be given to the angle of the anterior chamber. Glaucoma in 
this age group could be secondary to congenital conditions like Axenfeld-Reiger’s 
syndrome, Sturge Weber syndrome, Peter’s anomaly or aniridia.86 It may also be 
secondary to inflammatory conditions like uveitis or trauma. These may prove to be 
challenging in terms of management. 
Laser procedures offer the least risk to the unborn fetus. Advantages over incisional 
surgery are that it requires only topical anesthesia, can be performed in an upright 
position, is an outpatient procedure with very little pre- and post-operative medication 
requirement, and patients demonstrate faster rehabilitation, all of which are of advantage 
both in early and advanced stages of pregnancy.
87
 The most frequently done procedure is 
neodymium: yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy for narrow-
angle glaucoma.
88
 Another procedure performed on the iris is the laser peripheral 
iridoplasty in which laser burns are applied to the peripheral iris to facilitate widening of 
the anterior chamber angle or to lyse peripheral anterior synechiae.  Argon laser 
trabeculoplasty in which evenly spaced burns are placed on the anterior trabecular 
meshwork for 180 or even 360 degrees of the angle. It causes both structural and 
coagulative damage to the tissues of the trabecular meshwork.
89
 Selective laser 
trabeculoplasty, on the other hand, is less disruptive to the tissues. The laser-induced 
thermal damage is confined to pigmented areas within an irradiated tissue.
90
 Using 
micropulse diode laser, the thermal spread of laser energy and consequent coagulative 
damage can be avoided.
91 
However, laser filtration procedures are not very effective in 
controlling IOP in patients younger than 50 years of age.
92, 93
 
Surgery in Glaucoma  
Surgical options include traditional filtration surgery and minimally invasive glaucoma 
surgery (MIGS).  It should be noted that drugs used during surgical interventions and for 
postoperative care should be reviewed and considered as sources of risk. 
There are several risks to be considered when planning invasive filtration surgery in a 
pregnant glaucomatous patient. These include the risks of local and systemic anesthetic 
medications and pre- and post-operative medications.
94
 Inhaled anesthetic agents and 
central nervous system depressants used to anesthetize the patient can be harmful to the 
fetus. This is particularly true of general anesthetic agents, which have been shown to 
cause an increased incidence of low birth weight and neural tube defects when 
administered to the mother in her first trimester.
95 
Most local anesthetics have not been 
shown to be teratogenic in humans and are considered relatively safe for use during 
pregnancy. Lidocaine and etidocaine are classified as group B and bupivacaine and 
mepivacaine are in group C because they have a tendency to induce fetal bradycardia.
96
 
Retrobulbar anesthesia may produce more systemic absorption than subconjunctival and 
anterior sub-Tenon's anesthesia combined with topical anesthesia for glaucoma surgery.
96
 
Position of the patient during surgery is important especially in second and third trimester 
of pregnancy. The gravid uterus may compress the aorta or inferior vena cava and cause 
severe hypotension. To prevent this, the patient will need to be rotated towards the left 
side at the level of hips or thighs while keeping the head steady.
97
 
Failure rate following glaucoma filtration surgery is high due to the young age of the 
patient and physiological changes that occur naturally in pregnancy. Levels of vascular 
endothelial growth factor (VEGF) and placental growth factor (PGF) are elevated in 
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pregnancy and aid in cell migration of fibroblasts and inflammatory cells and promote 
proliferation favoring wound healing.
98 
However, the antimetabolites, which are 
commonly used following filtration surgery, such as Mitomycin C and 5 Fluorouracil are 
FDA category X teratogens and therefore are absolutely contraindicated in pregnancy.
99, 
100
 Filtration surgery without the use of antimetabolites, favors fibrosis of the incision site 
leading to increased chance of failure. An alternative would be MIGS and or aqueous 
shunt surgery for patients who need surgery in pregnancy.
101
 The Tube versus 
Trabeculectomy study has helped to highlight shunt surgery as an alternative to 
conventional filtration surgery.
102
 Over the last few years, advances in glaucoma surgery 
have expanded the surgical options available for a pregnant woman with glaucoma, 
requiring surgery. In MIGS, the ab interno approach prevents damage to the conjunctiva 
and helps to reduce the number of postoperative medications required. 
103 
It may also 
probably be safer compared to traditional filtration procedures. In addition, several micro 
stents are now available which help to increase aqueous outflow with less disturbance to 
the ocular structures. 
Management Plan 
Pre-conception counseling: Women in the childbearing age who have a history of 
glaucoma may already be on anti-glaucoma medications. If the pregnancy is unplanned, it 
can pose a risk to the fetus since the first trimester is the period of organogenesis and this 
may be adversely affected by the medication
7
. Hence preconception planning is ideal in 
women of childbearing age who have glaucoma. Counseling helps the woman understand 
the potential benefits and risks of various treatment modalities. This will help pave the 
way for better patient communication and cooperation, including more frequent 
evaluations of IOP levels, visual field examinations, and optic nerve evaluations, after the 
baseline evaluations. This, in turn, will help determine the course of management of 
glaucoma during pregnancy. If the glaucoma is well controlled the woman may be taken 
off the medication and observed during the course of her pregnancy or the number and 
frequency of medication may be reduced. In uncontrolled cases, the preconception stage 
is ideal for any intervention either laser trabeculoplasty or surgical intervention as the risk 
to the fetus is nil at this stage. 
First trimester: By the time the pregnancy is identified, organogenesis would have 
already started to occur. If pressures can be kept under control without treatment, close 
monitoring of IOP and visual fields would be the ideal option. Consideration of 
medications used during first trimester is crucial. Brimonidine, a category B drug, is the 
safest option and beta-blockers, although a category C drug, can also be used as a first 
line drug. Surgery may be best avoided in the first trimester. 
Second trimester: Beta-blockers and brimonidine can be used with close monitoring of 
the fetal heart rate and fetal growth during this period. Patient should be educated to 
watch for symptoms of premature labor if topical prostaglandin analogs are used.  
Third trimester: Beta-blockers and CAIs are the ideal medications to be used in this 
period if IOP lowering is needed. Brimonidine should be stopped late in the third 
trimester to avoid central nervous system depression in newborn. 
Lactation: Both beta-blockers and CAIs can be used during lactation, although beta-
blockers are best avoided if the baby has preexisting cardiac problems. Concerning 
prostaglandins, because of its short half-life, it is unlikely to cause any harm in breastfed 
infants 
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 Laser treatment options including trabeculoplasty can be considered if IOP is 
uncontrolled with medications. Trabeculoplasty: Argon laser, selective laser or 
micropulse diode laser trabeculoplasty can be performed for better control of IOP.  
Surgery: Filtration surgery can be performed with caution in second and third trimester if 
IOP is not controlled by medications and laser trabeculoplasty. 
Conclusion 
Managing glaucoma in pregnancy is a delicate balance between control of IOP to prevent 
damage to the optic nerve in the mother and avoidance of interventions that are 
potentially harmful to the fetus. Optimum treatment strategies for glaucoma in pregnancy 
should begin prior to conception and include careful consideration of risks to both the 
mother and fetus. Preservation of the optic nerve and vision in the mother are 
predominate considerations, however, considerations of risk to the unborn child must be 
carefully considered and discussed with the glaucoma patient.  Newer and less invasive 
surgical interventions such as MIGS may be novel options, however, postoperative 
medications still need to be considered during the management of glaucoma in 
pregnancy.  An open dialog and close relationship between clinician and females of 
child-bearing age about the risks and options of pregnancy in glaucoma is vital to 
producing best possible outcomes for all involved. 
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Class A 
Controlled studies show no risk. Adequate well-controlled studies in pregnant women have 
not shown any risk to the fetus 
Class B 
No evidence of risk in humans. Either animal studies have shown risk, but human studies 
have not or, if no adequate human studies have been done, animal studies are negative. 
Class C 
Risk cannot be ruled out. Human studies are lacking, and animal studies are either positive 
for fetal risk or inadequate as well. However potential benefits may outweigh the potential 
risk. 
Class D 
Definite evidence of risk. Investigational or post-marketing data show some risk to the 
fetus. But, potential benefits may outweigh the potential risk. 
Class X 
Contraindicated in pregnancy. Studies in animals or human or investigational or post-
marketing reports have shown fetal risk which clearly outweighs any benefit to the patient. 
Table 1: FDA Pregnancy Categories42 
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Table 2: Adverse Effects of Glaucoma Medications during Pregnancy and Breast-Feeding42 
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